Inpatient Antibiotic Treatment for Cellulitis
For hospitalized patients with complicated cellulitis, initiate IV vancomycin (15-20 mg/kg every 8-12 hours) as empirical therapy to cover MRSA, with a treatment duration of 7-14 days individualized to clinical response. 1, 2
Initial IV Therapy Selection
For Complicated/Hospitalized Cellulitis
The choice of initial IV antibiotic depends on whether the cellulitis is purulent or nonpurulent:
Purulent cellulitis (with drainage/exudate) or complicated SSTI requires empirical MRSA coverage with one of the following options 1, 2:
- IV vancomycin 15-20 mg/kg every 8-12 hours (A-I evidence)
- IV or PO linezolid 600 mg twice daily (A-I evidence)
- IV daptomycin 4 mg/kg once daily (A-I evidence)
- IV telavancin 10 mg/kg once daily (A-I evidence)
- IV or PO clindamycin 600 mg three times daily (A-III evidence)
Nonpurulent cellulitis without systemic toxicity may be treated with a β-lactam antibiotic such as IV cefazolin, with modification to MRSA-active therapy if no clinical response occurs (A-II) 1, 2.
For Severe/Necrotizing Infections
If there is concern for necrotizing fasciitis or severe systemic toxicity, use broad-spectrum empirical coverage 3:
- Vancomycin or linezolid PLUS piperacillin-tazobactam or a carbapenem
- Alternative: Vancomycin PLUS ceftriaxone and metronidazole
Treatment Duration
The recommended total duration is 7-14 days, but should be based on clinical response 1, 2. More recent evidence from the 2014 IDSA guidelines suggests 5 days may be sufficient if the infection has improved, with extension only if inadequate response 3, 4.
Key Point on Duration
The 2014 guidelines (the most recent) recommend 5 days as the standard duration, extending only if clinical improvement is insufficient 3. This represents an evolution from the earlier 2011 guidelines that recommended 7-14 days 1, 2.
Criteria for Switching to Oral Antibiotics
Switch from IV to oral therapy when the patient demonstrates clinical improvement, defined as 1, 2, 5:
- Afebrile (no fever)
- Cessation of cellulitis progression (no advancing erythema)
- Improved cellulitis severity (decreased warmth, tenderness, erythema, and edema)
- Able to tolerate oral intake
- Hemodynamically stable
Research supports that switching can occur as early as 24-72 hours if these criteria are met, with no increase in treatment failure 5, 6. One high-quality study demonstrated that oral cefalexin was non-inferior to IV cefazolin for uncomplicated cellulitis 6.
Oral Antibiotic Options After Switch
For nonpurulent cellulitis (streptococcal coverage):
- Cephalexin 500 mg four times daily
- Dicloxacillin 500 mg four times daily
- Amoxicillin 500 mg three times daily
For purulent cellulitis or MRSA coverage 1, 2:
- Clindamycin 300-450 mg three times daily (covers both streptococci and MRSA)
- TMP-SMX 1-2 double-strength tablets twice daily (add β-lactam for streptococcal coverage)
- Doxycycline 100 mg twice daily (add β-lactam for streptococcal coverage)
- Linezolid 600 mg twice daily (covers both streptococci and MRSA)
Important Clinical Caveats
When to Consider MRSA Coverage
Empirical MRSA coverage is indicated for 1, 3, 4:
- Purulent drainage or exudate
- Penetrating trauma
- Evidence of MRSA infection elsewhere or nasal colonization
- Injection drug use
- Systemic inflammatory response syndrome (SIRS)
- Failure to respond to β-lactam therapy
Surgical Consultation
Obtain prompt surgical consultation for patients with 3:
- Signs of necrotizing fasciitis or gas gangrene
- Aggressive infection with systemic toxicity
- Need for debridement
Culture Recommendations
Obtain blood cultures and wound cultures in hospitalized patients, particularly those with 1, 2:
- Severe local infection or systemic illness
- Purulent drainage
- Failure to respond to initial treatment
- Concern for outbreak
Common Pitfall
Avoid overtreatment of nonpurulent cellulitis with MRSA-active agents unless the patient has risk factors or fails β-lactam therapy. The majority of nonpurulent cellulitis is caused by β-hemolytic streptococci, not MRSA 1, 3, 7.